alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › tau-protein

tau-protein

387 studies tagged tau-protein, dated 1987-01-01 to 2026-10-31. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. APH-1A and CDK5 Expression Correlates with Tau Hyperphosphorylation and Its Attenuation by Brahmi and Donep-M in STZ induced Alzheimer’s Disease Model 2026-10-31
  2. Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions 2026-10-30
  3. The Alzheimer's disease-associated rs28834970 variant in PTK2B impairs electrical activity and regulates Tau phosphorylation and APP processing in human neuronal cultures 2026-10-30

Studies

387 studies carry this tag.

Date range

1987 to 2026

Top journals

  • Acta neuropathologica 16
  • Alzheimer's & dementia : the journal of the Alzheimer's Association 12
  • bioRxiv 12
  • Molecular neurodegeneration 10
  • Research Square 10

173 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. APH-1A and CDK5 Expression Correlates with Tau Hyperphosphorylation and Its Attenuation by Brahmi and Donep-M in STZ induced Alzheimer’s Disease Model

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-31 Genetics

    Alzheimer’s disease (AD) is a progressively characterized neurodegenerative condition marked by molecular instability, neuronal dysfunction and abnormal tau buildup.

  2. Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-10-30 Treatments

    Aggregation of the microtubule-stabilizing protein Tau into insoluble deposits is characteristic for several neurodegenerative diseases, including Alzheimer's disease.

  3. The Alzheimer's disease-associated rs28834970 variant in PTK2B impairs electrical activity and regulates Tau phosphorylation and APP processing in human neuronal cultures

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-10-30 Genetics

    The rs28834970 regulatory variant was identified as the most functionally relevant in our model, with the C risk allele promoting transcription factor C/EBPβ binding within a cis-regulatory element.

  4. Effect of Metformin on tau pathology and proteostasis in cellular and a Drosophila model of Tauopathy

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-29 Drug development

    Alzheimer’s disease is increasingly linked to metabolic dysfunction, with insulin resistance emerging as a key contributor to tau pathology.

  5. SHED-Derived Exosomes Attenuate Alzheimer's Disease Pathology in iPSC-Derived Cerebral Organoid Model

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-29 Biomarkers

    SHED exosome treatment demonstrated genotype-specific efficacy, selectively reducing p181-tau levels and restoring the p181-tau/Aβ42 ratio in FAD lines while elevating the protective Aβ42/Aβ40 ratio across both FAD and SAD backgrounds.

  6. Neuronal Hyperactivity Induces Tau Phosphorylation Selectively in Excitatory Pyramidal Neurons Which Contributes to GluA2 Regulation

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-10-28 Disease mechanisms

    While tau plays a role in regulating neuronal network excitability, a process thought to be dysregulated in Alzheimer’s disease (AD), the molecular mechanisms linking tau and hyperexcitability remain unclear.

  7. Second-generation tau PET tracer in situ binding assessed with fluorescence imaging

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-27 Brain scans and imaging

    Brain positron emission tomography (PET) imaging is a valuable tool which allows visualization of the pathological structures inside the living patients’ brains.

  8. Early Insulin Signaling Abnormalities and Oxidative Stress Responses in PS19 Tau Transgenic Mice

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-10-22 Inflammation and the immune system

    Pathological tau accumulation is a hallmark of Alzheimer’s disease (AD), yet its relationship with impaired insulin signaling remains unclear.

  9. NADPH attenuates tau pathology and disease-associated microglial phenotype in a truncated tau- induced mouse model

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-19 TREM2 and immune genetics

    Truncated tau is increasingly recognized as a pivotal pathogenic event in Alzheimer’s disease (AD).

  10. Depth-Dependent Alterations in Cerebral Blood and Tissue Oxygenation Associated with Tau in Alzheimer’s Disease Models

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-10-16 Vascular contributions

    Vascular dysfunction is increasingly recognized as a feature of Alzheimer’s disease (AD), and inadequate oxygen delivery may contribute to neuronal death.

  11. A First-in-Class, Brain-Penetrant Small Molecule Inhibitor of the NOS1AP-Tau Interaction Rescues Tau Pathology In Vivo and Improves Cognition

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-10-07 Biomarkers

    NOS1AP is a genetically validated driver of tau pathology in Alzheimer’s disease (AD), yet the NOS1AP-tau interaction itself has remained pharmacologically untargeted.

  12. Brain region- and solubility-dependent proteomic signatures of neurofibrillary tangle pathology in Alzheimer’s disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-10-07 Brain tissue and pathology

    Neurofibrillary tangles (NFTs) containing hyperphosphorylated tau proteins are a hallmark neuropathology of Alzheimer’s disease.

  13. Hypothalamic tau P301L pathology disrupts pair bonding in monogamous prairie voles

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-10-02 Caregiving

    Although dementias primarily affect memory, they also disrupt our closest social relationships, resulting in elevated caregiver burden and worse patient outcomes.

  14. In silico design and physicochemical characterisation of a dual-action intranasal nanoparticle formulation for Alzheimer’s disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-28 Treatments

    Approved Alzheimer’s disease therapies fail to address the two drivers of cognitive decline: loss of BDNF-TrkB signalling and accumulation of hyperphosphorylated tau protein.

  15. Cofilin Suppresses Tau-Induced Defects in Dense-Core Granule Formation and Aβ-Induced Neurodegeneration

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-09-27 Risk genes beyond APOE

    Intracellular neurofibrillary tangles formed from hyperphosphorylated tau and extracellular amyloid plaques containing aggregated Aβ-peptides, specific cleavage products of the Amyloid Precursor Protein (APP), are the primary histopathological hallmarks of Alzheimer’s Disease (AD), the leading cause of dementia in humans.

  16. Soluble pathogenic tau transmission to astrocytes drives cellular senescence and neurovascular uncoupling in a model of Alzheimer’s tauopathy

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-09-12 Disease mechanisms

    Pathogenic tau oligomers are transmitted between neurons and non-neuronal cells and may contribute to cellular dysfunction in Alzheimer’s disease (AD).

  17. Disease-specific tangle immunophenotypes distinguish hippocampal vulnerability in Alzheimer’s disease and Parkinson’s disease dementia

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-08-19 Lewy body dementia

    Structured Abstract INTRODUCTION Tau pathology typically occurs in Alzheimeŕs disease (AD), however is also frequently present in Parkinsońs disease dementia (PDD) and Dementia with Lewy Bodies (DLB), yet its disease-specific signature is unclear.

  18. Taulipro rescues mitochondrial dysfunction and inhibits cGAS–STING neuroinflammation in Aβ-driven Alzheimer's disease models

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-08-14 Drug development

    Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder for which effective multitarget therapies remain unavailable.

  19. Active amyloid beta immunization ameliorates synapse loss and phosphorylated-tau accumulation around remaining plaques for up to 14 years after treatment

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-08-11 Treatments

    Amyloid plaques, one of the defining features of Alzheimer’s disease, are associated with synapse loss and accumulation of pathological tau in dystrophic neurites and reactive glia in their immediate vicinity.

  20. Chronic orexin receptor antagonism is associated with rescued sleep and agitation-like behaviour in tau transgenic PS19 mice, but sex-dependently improved cognition

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Authorea Preprints 2026-07-25 Risk factors

    DORA-22 and MK-1064 rescued tauopathy-related sleep loss, and reduced agitation-like locomotion and stress-induced hyperthermic responses.

  21. Serum phosphorylated tau 217 in GBA1 variant carriers with and without Parkinson disease

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Parkinson's disease 2026-01-22 Biomarkers

    It is unclear whether Alzheimer disease pathology drives cognitive decline in Parkinson disease (PD) patients carrying GBA1 variants.

  22. Plasma p-tau species are elevated in presymptomatic and symptomatic neuronal intranuclear inclusion disease

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. EBioMedicine 2026-01-14 Biomarkers

    P-tau217, p-tau231, p-tau181, α-syn, NfL, and GFAP levels were elevated in patients with NIID compared with HCs; p-tau species and GFAP were also upregulated in preNIID.

  23. CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures

    ✓ Peer-reviewed alzhub usefulness score 84 out of 100. Brain : a journal of neurology 2026-01-08 Drug development

    Targeting of tau pathology has long been proposed as a potential therapeutic strategy for Alzheimer's disease (AD).

  24. Evaluation of [18F]MK-6240 binding to tau protein in postmortem human brains of Down syndrome and Alzheimer’s disease and assessment of off-target (non-tau) binding

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-01-06 Drug development

    Alzheimer's disease (AD) and Down Syndrome (DS) are characterized by the aggregation of tau tangles.

  25. The evolving landscape of Alzheimer's disease therapy: From Aβ to tau

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Cell 2025-12-24 Drug development

    A marked evolution in Alzheimer's disease (AD) therapy research is ongoing.

  26. Plasma p-Tau217 and p-Tau181 levels in Well-Controlled versus Drug-Resistant focal epilepsy

    ✓ Peer-reviewed alzhub usefulness score 54 out of 100. Epilepsy & behavior : E&B 2025-12-11 Biomarkers

    Plasma was collected from 103 patients: 48 well-controlled (C, 31.3 % female) and 55 drug-resistant (DR, 50.9 % female).

  27. Conformation-based detection of tau seeds with a novel VHH

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2025-12-08 Drug development

    In Alzheimer’s disease (AD) and related tauopathies, progressive pathology has been linked to prion mechanisms whereby ordered tau assemblies, or “seeds,” form in one cell and transit to neighboring or connected cells where they serve as templates for their own replication.

  28. Human Wild-Type α-Synuclein Drives Progressive Tau Pathology in a Disease-Relevant Mouse Model of Synucleinopathy

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research square 2025-12-03 Brain tissue and pathology

    Tau pathology, characterized by the aberrant aggregation and accumulation of tau in neurons and glial cells, plays a critical role in the onset and progression of multiple neurodegenerative diseases.

  29. Nanobodies targeting hnRNPA2/B1 and tau

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv : the preprint server for biology 2025-11-24 Drug development

    Heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2/B1) is an RNA-binding protein that mislocalizes to the cytoplasm and forms stress-induced granules in tauopathy and multisystem proteinopathy.

  30. PolyGR-containing aggregates link with pathology and clinical features of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Acta neuropathologica 2025-11-08 Brain tissue and pathology

    Alzheimer's disease is the most common form of dementia; however, its molecular mechanisms are not fully understood.

  31. Tau biology, biomarkers, and therapeutics

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer's & dementia (New York, N. Y.) 2025-10-21 Drug development

    As Alzheimer's disease (AD) research advances, tau has emerged as both a critical biomarker and a promising therapeutic target, central to understanding disease mechanisms, tracking progression, and guiding treatment development.

  32. Reversible tau hyperphosphorylation in hibernation: a blood biomarker and brain tissue study

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Acta neuropathologica 2025-09-29 Biomarkers

    Tau hyperphosphorylation, a key neuropathological feature of tauopathies such as Alzheimer's disease (AD), also occurs physiologically during mammalian hibernation and is fully reversed upon arousal, offering a unique translational model to study tau metabolism.

  33. Generation of a recombinant GST-Tau antigen for indirect ELISA in evaluating Alzheimer’s disease vaccines

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2025-09-20 Drug development

    A robust method was developed to produce and optimize GST-Tau as a coating antigen for indirect ELISA.

  34. Understanding Tau pathology: Insights from animal models

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Zoological research 2025-09-18 Drug development

    Tauopathies represent a class of neurodegenerative diseases (NDs), including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), Pick's disease (PiD), and corticobasal degeneration (CBD), defined by intracellular accumulation of misfolded and hyperphosphorylated tau protein.

  35. mRNA vaccine platform demonstrates potent immunotherapeutic targeting of amyloid-β and tau pathologies in Alzheimer's disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2025-09-16 Drug development

    Current Alzheimer’s disease (AD) immunotherapeutics face efficacy and safety limitations with antibody-based approaches.

  36. Biomarker-related phospho-tau217 appears in synapses around Aβ plaques prior to tau tangle in cerebral cortex of preclinical Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Cell reports 2025-09-02 Biomarkers

    Phospho-tau protein p-tau181 is a cerebrospinal fluid biomarker for Alzheimer's disease (AD), while p-tau217 is the most sensitive plasma biomarker for cerebral amyloid β (Aβ) load prior to tau pathology in preclinical AD.

  37. The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology

    ✓ Peer-reviewed alzhub usefulness score 82 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-09 Biomarkers

    Phosphorylated tau (p-tau) species (153, 181, 217, 231) increased early in preclinical AD but were reduced with gantenerumab-mediated Aβ plaque reduction.

  38. GLP-1 receptor agonist semaglutide ameliorates motor deficits and tau pathology in the rTg4510s mouse model

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neuropharmacology 2025-08-27 Drug development

    Semaglutide significantly improved motor coordination in rTg4510 mice on the pole test, though not rotarod endurance.

  39. Single-Domain Antibody-Based Autophagosome-Targeting Chimera for Tau Clearance and Motor Function Restoration in Tauopathies

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2025-07-04 Drug development

    Tauopathies are neurodegenerative diseases characterized by pathological tau accumulation, leading to motor and neuropsychiatric symptoms.

  40. Genome-wide association of tau neuroimaging and plasma biomarkers in adults with Down syndrome

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-07 Genetics

    Three genome-wide significant associations were identified for p-tau181: TUBAP/rs76523946, P = 2.21E-08; CTNND2/rs142510573, P = 3.04E-08; CLSTN2/rs112448655, P = 3.04E-08, and one for t-tau (JHY/rs77264104, P = 2.84E-08).

  41. Mitochondrial DNA affects tau phosphorylation in aging and Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-07 Biomarkers

    Relative to cybrids expressing mtDNA from CH individuals, MCI and AD cybrids contained more phosphorylated tau-217 (p-tau217), p-tau181, and total tau.

  42. Large-scale single-molecule analysis of tau proteoforms

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Nature methods 2025-06-27 Drug development

    Proteins exist as diverse proteoforms resulting from a combination of genetic variation, alternative splicing, and post-translational modifications.

  43. Updates on Tau-Related Drug Targets and Potential Disease-Modifying Therapies for Alzheimer Disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. The American journal of pathology 2025-06-19 TREM2 and immune genetics

    Alzheimer disease (AD) is a chronic, multifactorial neurodegenerative disease affecting a large proportion of the elderly population with detrimental psychological and socioeconomic impacts.

  44. A High-Throughput Drug Screening Assay for Anti-Tau Aggregation Using Split GFP and Flow Cytometry

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Scientific reports 2025-06-18 Drug development

    Tau protein aggregation is a hallmark of neurodegenerative diseases, including Alzheimer's disease, making the development of anti-aggregation therapeutics a critical area of research.

  45. In Silico Design and Molecular Docking of Dalfina: A Tau-Targeting Small Molecule for Alzheimer's Disease Therapy

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Authorea Preprints 2025-06-03 Drug development

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by abnormal aggregation of the tau protein.

  46. Synaptotoxic effects of extracellular tau are mediated by its microtubule-binding region

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Acta neuropathologica 2025-06-02 Disease mechanisms

    Immunotherapies targeting extracellular tau share the premise that interrupting cell-to-cell spread of tau pathology in Alzheimer's disease (AD) will slow dementia pathogenesis.

  47. Tau phosphorylation at Alzheimer's disease biomarker sites impairs its cleavage by lysosomal proteases

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-06 Biomarkers

    Phosphorylation renders the PRD significantly resistant to cleavage by the lysosome, especially at less acidic pH setpoints.

  48. Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of translational medicine 2025-05-30 Treatments

    DO11.10 cells expressing E2814-CAR-but not Lec-CAR-responded to tau PFFs.

  49. Cell-death pathways and tau-associated neuronal vulnerability in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Cell reports 2025-05-29 Genetics

    Neuronal loss is the ultimate driver of neural system dysfunction in Alzheimer's disease (AD).

  50. Tau aggregation induces cell death in iPSC-derived neurons

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Aging brain 2025-04-11 Drug development

    Abnormal accumulation of tau proteins in the brain is a hallmark of neurodegenerative diseases such as Alzheimer's disease and is closely linked with neuronal cell death.

From across this tag

7 of the 387 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 7. The same 7 appear here every time.

All topic tags with their study counts